Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level Patient experienced only Grade 1 adverse events  Represents second patient with PR to harbor PPP2R1A mutation, supporting mechanistic thesis of targeting WEE1 for this patient population Emerging clinical proof of concept responses without class-limiting toxicity to date support Aprea's development strategy of differentiated WEE1 inhibition with an improved therapeutic index DOYLESTOWN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced additional preliminary data from the ongoing Phase 1 ACESOT-1051 trial evaluating its investigational WEE1 kinase inhibitor APR-1051.

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea's WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045.

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051 Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051